The tweet was deleted by the author.
But we saved everything 🙂.
Fulgent Genetics reported a significant expansion of its genetic testing panels, adding 188 genes to its skeletal dysplasia panel and 29 to its vascular malformation panel last month.
The broader coverage aims to improve diagnostic options for patients with rare diseases. Fulgent Genetics also invited feedback from clinicians on how expanded panels may have changed the diagnostic path for their patients, encouraging engagement on the impact of such advances.
View post on X Loading...
Fulgent Genetics has recently increased its genomics outreach through research publications, podcasts, and conference presentations, as detailed in company disclosures. The firm has also updated its protocols for genetic variant reclassification and issued recommendations on the use of segregation testing, according to previous company guidance. These activities reflect ongoing efforts to support clinicians and enhance genetic testing practices.